MORGAN STANLEY PLC/CALL/AMGEN/260/0.1/20.12.24 | Market Closed - Börse Stuttgart 14:31:34 2024-07-05 EDT | ||
| 5.62 EUR | +2.00% |
|
| Current month | -3.10% | ||
| 1 month | +0.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 5.62 | +2.00% |
| 24-07-04 | 5.51 | -0.54% |
| 24-07-03 | 5.54 | -4.97% |
| 24-07-02 | 5.83 | +0.87% |
| 24-07-01 | 5.78 | -0.34% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 02:31 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB16YJ |
| ISIN | DE000MB16YJ5 |
| Date issued | 2022-12-05 |
| Strike | 260 $ |
| Maturity | 2024-12-20 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 6.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.13 € |
|---|---|
| Lowest since issue | 0.88 € |
| Spread | 0.03 € |
| Spread % | 0.53% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.9
USD
Average target price
316.4
USD
Spread / Average Target
+1.79%
- Stock Market
- Warrants
- Warrant
